Insmed Announces Podium Presentation at the Pediatric Academic Societies' 2006 Annual Meeting
26 Avril 2006 - 4:00PM
PR Newswire (US)
RICHMOND, Va., April 26 /PRNewswire-FirstCall/ -- Insmed
Incorporated (NASDAQ:INSM) announced today that preliminary data
from a prospective, multicenter clinical trial using
rhIGF-I/rhIGFBP-3 (IPLEX) administered once daily to children with
Severe Primary IGF-1 deficiency will be presented during a podium
presentation at the Pediatric Academic Societies' (PAS) 2006 Annual
Meeting. The meeting is being held from April 29 - May 2 at the
Moscone Center in San Francisco, Calif. The presentation, entitled
rhIGF-I/rhIGFBP-3 (IPLEX) Administered Once Daily in Children with
IGF-I Deficiency Due to Growth Hormone Insensitivity: Preliminary
Data from a Prospective, Multicenter Clinical Trial, will be
presented by Kenneth M. Attie, MD. The presentation will highlight
the 12 month Height Velocity data from once daily treatment with
IPLEX (rhIGF-I/rhIGFBP-3) in children with Severe Primary IGF-I
deficiency. Treatment with IPLEX demonstrated statistically
significant, dose dependent increases in Height Velocity with a
favorable safety profile. The presentation will take place as part
of PAS on Monday, May 1 at 10:45 a.m. PT, Room 3007-3011, Moscone
West. About IPLEX IPLEX, a complex of rhIGF-1 and rhIGFBP-3, is the
only once-daily IGF-1 replacement therapy and the only therapy that
provides both IGF-1 and IGFBP-3 that is approved by the FDA to
treat children with severe Primary IGFD. The drug, expected to
launch during the second quarter of calendar year 2006, is also
being studied for various other indications with unmet medical
needs including extreme insulin resistance, myotonic muscular
dystrophy and HIV Associated Adipose Redistribution Syndrome
(HARS). About the Condition Severe Primary IGFD is a genetic
condition in which patients do not generate sufficient quantities
of insulin-like growth factor-I (IGF-1) and insulin-like growth
factor binding protein-3 (IGFBP-3), two key proteins involved in
mediating the effects of growth hormone. Patients with severe
Primary IGFD present with extreme short stature (height standard
deviation score, SDS < -3) and an extremely poor prognosis for
adult stature. Whereas prepubertal height SDS can range as low as
-9, a blunted pubertal growth spurt is usually apparent, resulting
in adult height that is typically 5-12 SD's below the normal
population (adult height between 100 and 140 cm). The profound
short stature in patients is often associated with severe
psychosocial problems. About Insmed Incorporated Insmed is a
biopharmaceutical company focused on the discovery and development
of drug candidates for the treatment of metabolic diseases and
endocrine disorders with unmet medical needs. For more information,
please visit http://www.insmed.com/. Statements included within
this press release, which are not historical in nature, may
constitute forward-looking statements for purposes of the safe
harbor provided by the Private Securities Litigation Reform Act of
1995. Forward-looking statements in this press release include, but
are not limited to, statements regarding planned clinical trial
design, our regulatory and business strategies, plans and
objectives of management and growth opportunities for existing or
proposed products. Such forward-looking statements are subject to
numerous risks and uncertainties, including risks that product
candidates may fail in the clinic or may not be successfully
marketed or manufactured, the company may lack financial resources
to complete development of product candidates, the FDA may
interpret the results of our studies differently than we have,
competing products may be more successful, demand for new
pharmaceutical products may decrease, the biopharmaceutical
industry may experience negative market trends and other risks
detailed from time to time in the company's filings with the
Securities and Exchange Commission. As a result of these and other
risks and uncertainties, actual results may differ materially from
those described in this press release. For further information with
respect to factors that could cause actual results to differ from
expectations, reference is made to reports filed by the Company
with the Securities and Exchange Commission under the Securities
Exchange Act of 1934, as amended. The forward-looking statements
made in this release are made only as of the date hereof and Insmed
disclaims any intention or responsibility for updating predictions
or financial guidance contained in this release. DATASOURCE: Insmed
Incorporated CONTACT: Mark Undercoffler, +1-415-984-6172, , or
Natalie Wyeth, +1-202-835-9473, , or Investor Relations: Tim Ryan,
+1-212-477-9007 x24, , all for Insmed Incorporated Web site:
http://www.insmed.com/
Copyright
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024